Pharmaco - Press Releases

Date	Title	Company
11-Oct-2023	The PolG Foundation awards over $3.5M in academic grants to pioneer POLG research	PolG Foundation
11-Oct-2023	eXmoor completes expansion into full-service cell and gene therapy CDMO partner with opening of GMP facilities	eXmoor pharma
11-Oct-2023	Almirall's Ilumetri® (tildrakizumab) significantly improves wellbeing for patients1 and their relatives2 in moderate-to-severe plaque psoriasis	Almirall S.A.
11-Oct-2023	Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark	Mainz BioMed N.V.
11-Oct-2023	The PolG Foundation Awards Over $3.5M in Academic Grants to Pioneer POLG Research	B3C newswire
11-Oct-2023	Oxford BioTherapeutics Relocates UK Headquarters to Strategic and Cutting-Edge R&D Location at The Oxford Science Park to Accelerate Development of its Immuno-Oncology and ADC-Based Cancer Therapies	Oxford BioTherapeutics
11-Oct-2023	ANALYSIS LINKS INFLAMMATORY BIOMARKER TO NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD), REINFORCES EFFICACY OF UPLIZNA® (INEBILIZUMAB) IN REDUCING DISEASE-RELATED ATTACKS	Amgen
11-Oct-2023	Biocomposites announces new territories approved to promote STIMULAN as an antibiotic carrier in bone and soft tissue	Biocomposites
11-Oct-2023	MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus	MinervaX
11-Oct-2023	Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis	Bristol Myers Squibb
11-Oct-2023	Roche’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions	Roche
11-Oct-2023	Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies	Roche
11-Oct-2023	Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis	Novo Nordisk
11-Oct-2023	AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023	AbbVie
11-Oct-2023	Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease	Merck
11-Oct-2023	Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)	Merck
10-Oct-2023	Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company's Assets and Adjustment of Guidance for 2023	Epigenomics AG
10-Oct-2023	Epigenomics AG: Closing of Agreement on the Acquisition of Almost All Assets and Adjustment of Guidance for 2023	Epigenomics AG
10-Oct-2023	Valo Therapeutics Announces Acquisition of Bruker Corporation’s Latest Mass Spectrometer Platform for Tumor Antigen Identification with ValoTx’s PeptiCHIP Technology	Valo Therapeutics
10-Oct-2023	GPCR Therapeutics Expands Pipeline into Fibrosis with a Combination Approach Targeting LPA1	GPCR Therapeutics